“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants 12. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. The nanoparticle loaded with medication could eliminate the need for a…
Macular Degeneration is the leading cause of blindness and vision loss in people over 50 –and with life expectancies well into the 80s, it is estimated that 1 and 3 elderly individuals will have to deal with this degenerative disease. The remedy? Monthly injections (via needle) into the back of the eye, where the disease…
The human brain has 100 billion neurons, connected to each other in networks that allow us to interpret the world around us, plan for the future, and control our actions and movements. MIT neuroscientist Sebastian Seung wants to map those networks, creating a wiring diagram of the brain that could help scientists learn how we…
Among patients who visited an ophthalmologist over an 8-year period, those with a current prescription for a fluoroquinolone were 4.5 times more likely to have a retinal detachment…The mechanism underlying the association is unknown but is presumed to be related to the destructive effects of fluoroquinolones on collagen and connective tissue. http://www.medpagetoday.com/Ophthalmology/GeneralOphthalmology/32011
Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials. Earlier this month, Novartis announced that the U.S. Food and Drug Administration accepted the company’s brolucizumab application for the treatment of nAMD. Reductions in central subfield thickness (CST) on optical coherence…
WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) — pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored Phase 2 study of pSivida’s Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the two years…